We help oncology laboratory pharma professionals enhance patient care
Oncology professionals
We ensure NGS testing is simple to organise with timely results provided in a timely way signposting you to treatment choices that will benefit your patients.
Laboratory professionals
Our solutions always ensure that NGS testing and its clinical interpretation is delivered in a timely way for the benefit of patients.
Pharma professionals
We can gather the information needed to precisely match patients to drugs, evidencing clinical efficacy, safety and patient benefit.
Years of trust, countless tests run, genes, and trials explored.
Our mission
OncoDNA’s ultimate mission is to improve all patients’ health by empowering healthcare providers, biopharma companies and researchers to deliver the promise of precision medicine. In this relentless pursuit of better care, we have been building an ecosystem of partners involved along the entire value chain – from translational research and drug development to patient treatment, monitoring and reimbursement.
Every day, our dedicated efforts focus on enhancing patient
access to Precision Medicine.
Comprehensive Genomic Profiling of Solid Tumor Patients for Broad Analysis in clinical diagnostics – A Comparative Analysis of OncoDEEP® Kit and Illumina TSO500
Comprehensive Pan-tumor Solution Comprehensive pan-tumor profiling of solid tumor is made possible with OncoDEEP® DNA and RNA Kit solutions. Designed for use with the powerful Next Generation Sequencing (NGS) technology, OncoDEEP® Kits can easily and...
DigiONE : A European digital research network for oncology
The rise of data standardisation in oncology with DigiONE Oncology is undergoing a major digital transformation. One of the most significant advances in this field is data standardisation, a process that DigiONE, the European digital...
Leading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument.
Leading French and European comprehensive cancer center selects the OncoDEEP® Kit as the most complete solution with the highest number of relevant oncology biomarkers for use in its molecular laboratory. Gosselies, Belgium and Paris,...
OncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing services
In the ever-evolving landscape of oncology clinical trials, the pursuit of precision has become synonymous with progress. In this era where tailored therapies hold the promise of improved patient outcomes, the foundation of reliable and...
February: 40-year-old male with a stage IV glioma cancer
OncoDEEP® identifies rare mutations & personalizes treatment for a 40-year-old male with a stage IV glioma cancer
Advancing personalized cancer treatment: Webinar Replay
Webinar replay available now: Unlocking precision medicine through expert NGS panel design Discover the Future of Personalized Cancer Treatment Thank you for your interest in our groundbreaking webinar on the latest advancements in cancer research...
Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer
Introduction: The integration of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (CX) marks a pivotal advancement in treating localized muscle-invasive bladder cancer (MIBC). Despite these efforts, approximately 45% of MIBC patients experience metastatic recurrence within...
Advancing personalized cancer treatment: explore the synergy of Twist Bioscience and OncoDNA in our webinar
Unlocking precision medicine through expert NGS panel design Tuesday, February 13, 20244:00 PM CEST By Dr. Marcel Trautmann, Koenraad Eycken, Dr. James Flynn Join our webinar to discover revolutionary insights into personalised cancer treatment with...
Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccine
Medical research is taking a quantum leap forward with the PDC*neo+ project, promising a significant progress in the treatment of colorectal cancer. Thanks to OncoDNA’s unique expertise in neoantigen identification and circulating tumour DNA (ctDNA)...